Why is survival after pembrolizumab affected by previous radiotherapy? - Authors' reply

Affiliations

¹ Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA. Electronic address: percylee@mednet.ucla.edu.
² Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA.

Comment

Percy Lee et al. Lancet Oncol. 2017 Sep.

. 2017 Sep;18(9):e505.

doi: 10.1016/S1470-2045(17)30588-0.

¹ Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA. Electronic address: percylee@mednet.ucla.edu.
² Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA.

No abstract available

Comment on

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Shaverdian N, et al. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. Lancet Oncol. 2017. PMID: 28551359 Free PMC article. Clinical Trial.
Why is survival after pembrolizumab affected by previous radiotherapy?
Manapov F, Roengvoraphoj O, Eze C. Manapov F, et al. Lancet Oncol. 2017 Sep;18(9):e504. doi: 10.1016/S1470-2045(17)30472-2. Lancet Oncol. 2017. PMID: 28884692 No abstract available.